Tianjin Da Ren Tang 9M 2026 Profit Attributable to Parent Falls 57% to RMB 916.83 MillionPUBT·Oct 30, 2026 at 09:30 AM600329-0.33%T14-0.78%
Tianjin Da Ren Tang Board Approves Related-Party New Media Promotion AgreementPUBT·Oct 30, 2026 at 09:28 AM600329-0.33%T14-0.78%
Tianjin Pharmaceutical Da Ren Tang announces HY2026 interim results release for six months ended June 30, 2026PUBT·Aug 26, 2026 at 09:19 AM600329-0.33%T14-0.78%
Hunan High-Tech Industry Investment chair Li Aidong visits Tianjin Pharma for operations reviewPUBT·Aug 10, 2026 at 04:09 PM600329-0.33%T14-0.78%
Tianjin Pharmaceutical Da Ren Tang enters annual distribution deal with Taiping Medicine, Zhongxin MedicinePUBT·Aug 7, 2026 at 12:42 PM600329-0.33%T14-0.78%
Tianjin Pharmaceutical Da Ren Tang unit wins China approval for saxagliptin-metformin sustained-release tabletsPUBT·Aug 7, 2026 at 12:41 PM600329-0.33%T14-0.78%
Ultra-high dividend yield stocks exposed, 47 stocks with the latest dividend yield exceeding 5%36Kr·Apr 3, 2026 at 12:23 AM600329-0.33%600690+2.17%
With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibitedWallstreetcn·Jan 27, 2026 at 10:41 AM512290-1.79%159929-0.99%
TJ DaRenTang announced its semi-annual performance, with a net profit attributable to the parent company of 1.928 billion yuan, a year-on-year increase of 193.08%Zhitong·Aug 14, 2025 at 08:31 AM600329-0.33%T14-0.78%
Some traditional Chinese medicine stocks saw their net profits double year-on-year in the first half of the yearZhitong·Aug 1, 2025 at 02:26 PM600671-1.81%600329-0.33%
TJ DaRenTang: Tongmai Yangxin Pills strongly recommended in the Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Coronary Microvascular DiseaseZhitong·Jul 18, 2025 at 02:17 PM600329-0.33%T14-0.78%
TJ DaRenTang: Expected net profit in the first half of 2025 to increase by 180%-204% year-on-yearZhitong·Jul 14, 2025 at 08:30 AM600329-0.33%T14-0.78%
TJ DaRenTang announced its first-quarter performance, with a net profit attributable to the parent company of 374 million yuan, a year-on-year decrease of 3.38%Zhitong·Apr 29, 2025 at 02:21 PM600329-0.33%T14-0.78%
